Phase II trial of chloroquinoxaline sulfonamide (CQS) in patients with stage III and IV non small-cell lung cancer
Academic Article
Overview
MeSH Major
Antineoplastic Agents
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Quinoxalines
Sulfanilamides
abstract
When given on this schedule CQS is inactive in NSCLC despite the fact that the target concentration was achieved in 90% of patients. The ability of the HTCFA to identify active agents remains unproved.
